Master nuclear cardiology with ACC’s expert-led, on-demand courses covering imaging, physics, and workflows — earn CME and stay current in clinical practice.

The American College of Cardiology (ACC) and OpenEvidence are entering a strategic partnership to accelerate the translation of cardiovascular clinical guidance and research into clinical ...

The U.S. Food and Drug Administration (FDA) announced on May 1 that the Apple Atrial Fibrillation (AFib) History Feature now qualifies as a Medical Device Development Tool (MDDT) to assess AFib burden ...

Whether you like your eggs sunny-side up, hard boiled or scrambled, many hesitate to eat them amid concerns that eggs may raise cholesterol levels and be bad for heart health. However, results from a ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease ...

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) final rule. The conversion factor for practitioners participating in a qualified ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called ...

The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) final rule, updating the PFS conversion factor from $32.3465 to $33.5675 for qualifying ...

The U.S. Food and Drug Administration (FDA) has approved Cardamyst™ (etripamil) nasal spray to treat adults with paroxysmal supraventricular tachycardia (PSVT). This rapid-acting, self-administered ...